Login / Signup

Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis.

Laurence W BusseGina NicholsonRobert J NordykeCho-Han LeeFeng ZengTimothy E Albertson
Published in: International journal of technology assessment in health care (2020)
For treatment of severe distributive shock, angiotensin II is cost-effective at acceptable thresholds.
Keyphrases
  • angiotensin ii
  • angiotensin converting enzyme
  • vascular smooth muscle cells
  • early onset
  • replacement therapy